Literature DB >> 20455039

[Inflammatory myofibroblastic tumor of the lymph node with paraneoplastic thrombosis and eosinophilia].

Ali Behzad1, Andrea Müller, Wolf Rösler, Kerstin Amann, Rainer Linke, Andreas Mackensen.   

Abstract

CASE REPORT: A 52-year-old female patient was admitted to hospital because of progressive thrombosis despite therapeutic anticoagulation as well as leukocytosis with eosinophilia and thrombocytopenia. On examination, the patient presented with dyspnea and swelling oft her left leg and arm. The laboratory findings revealed leukocytosis (31,000/microl) with eosinophilia (54%), thrombocytopenia (58,000/microl), together with an increased C-reactive protein of 247 mg/dl (reference range < 5 mg/dl). Initial computed tomography scans showed pulmonary embolism and a slightly enlarged left inguinal lymph node. Histological examination of the lymph node biopsy revealed in part an epitheloid and spindle cell-like tumorous lesion with slightly increased tissue eosinophilia consistent with an inflammatory myofibroblastic tumor (IMT). Resection of the left inguinal lymph node resulted in an immediate regression of the paraneoplastic eosinophilia and thrombocytopenia. Anti-inflammatory medication with ibuprofen was subsequently initiated. Imaging and clinical examination at 3 months after discharge revealed no relapse and no signs of a paraneoplastic syndrome.
CONCLUSION: The IMT is a rare soft-tissue tumor of intermediate dignity with a low tendency to metastasize. It is consistently accompanied by paraneoplastic syndromes. Therapy of choice is complete resection of the tumor. In nonresectable cases, corticosteroids and nonsteroidal antirheumatics have been shown to be effective. Because of the variable clinical course ranging from spontaneous regression to metastasis, IMTs might be separated into different entities (autoimmune, inflammatory, neoplastic subtype) which thus far cannot be classified on a histopathologic basis. A clinical assessment of the dignity is therefore important until further subclassifications of this rare disease become available.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20455039     DOI: 10.1007/s00063-010-1030-x

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  23 in total

1.  Regression of nonresectable inflammatory myofibroblastic tumours after treatment with nonsteroidal anti-inflammatory drugs.

Authors:  R Przkora; U Bolder; S Schwarz; K W Jauch; J Spes; R Andreesen; A Mackensen
Journal:  Eur J Clin Invest       Date:  2004-04       Impact factor: 4.686

2.  The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study.

Authors:  Harry Applebaum; Mark W Kieran; Timothy P Cripe; Cheryl M Coffin; Margaret H Collins; Arja Kaipainen; Andrea Laforme; Robert C Shamberger
Journal:  J Pediatr Surg       Date:  2005-06       Impact factor: 2.545

3.  Inflammatory pseudotumor of lymph node and spleen: an entity biologically distinct from inflammatory myofibroblastic tumor.

Authors:  J L Kutok; G S Pinkus; D M Dorfman; C D Fletcher
Journal:  Hum Pathol       Date:  2001-12       Impact factor: 3.466

4.  Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease.

Authors:  Yoh Zen; Takahiko Fujii; Yasunori Sato; Shinji Masuda; Yasuni Nakanuma
Journal:  Mod Pathol       Date:  2007-06-15       Impact factor: 7.842

5.  Classic follicular dendritic reticulum cell tumor of the lymph node developing in a patient with a previous inflammatory pseudotumor-like proliferation.

Authors:  Antonio Cossu; Amelia Lissia; Maria Filomena Dedola; Angelo Deiana; Rossana Faedda; Giuseppe Palmieri; Francesco Tanda
Journal:  Hum Pathol       Date:  2005-02       Impact factor: 3.466

6.  Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study.

Authors:  Hidetaka Yamamoto; Hiroshi Yamaguchi; Shinichi Aishima; Yoshinao Oda; Kenichi Kohashi; Yumi Oshiro; Masazumi Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  2009-09       Impact factor: 6.394

Review 7.  Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum?

Authors:  Liang Cheng; Stephanie R Foster; Gregory T MacLennan; Antonio Lopez-Beltran; Shaobo Zhang; Rodolfo Montironi
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

8.  Plasma cell granuloma of the lung.

Authors:  J D Urschel; T A Horan; H W Unruh
Journal:  J Thorac Cardiovasc Surg       Date:  1992-10       Impact factor: 5.209

Review 9.  Soft tissue tumors: new perspectives on classification and diagnosis.

Authors:  Kathrin Katenkamp; Detlef Katenkamp
Journal:  Dtsch Arztebl Int       Date:  2009-09-25       Impact factor: 5.594

10.  Absence of human herpesvirus-8 in pulmonary inflammatory myofibroblastic tumor: immunohistochemical and molecular analysis of 20 cases.

Authors:  Fabio Tavora; Konstantin Shilo; Irem H Ozbudak; Jean M Przybocki; Guanghua Wang; William D Travis; Teri J Franks
Journal:  Mod Pathol       Date:  2007-07-20       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.